Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00117403 · ClinicalTrials.gov registry record · Phase 1
Anti-Oxidant Treatment of Alzheimer's Disease
A Phase 1 study, sponsored by National Institute on Aging (NIA).
- Completed
- Registry status
- Phase 1
- Development phase
- 75
- Enrollment target
NCT00117403 is a Phase 1 study that has completed, run by National Institute on Aging (NIA). The registered enrollment target is 75 participants.
The verdict
NCT00117403, a Phase 1 study, has completed, sponsored by National Institute on Aging (NIA).
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 75 participants
- Enrollment target
Study Summary
The purpose of this study is to examine the safety and effectiveness of two anti-oxidant treatment regimens in patients with mild to moderate Alzheimer's disease. The anti-oxidant treatments include vitamin E + C + alpha-lipoic acid, and Coenzyme Q (CoQ).
Interventions
- DRUG Placebo capsules
- DRUG Vitamin E, Vitamin C, and Alpha-lipoic Acid
- DRUG Coenzyme Q
- DRUG Placebo wafers
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 75 participants |
| Start Date | 2006-01 |
| Est. Completion | 2007-09 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00117403
The ClinicalTrials.gov registry entry for NCT00117403 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 75 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Institute on Aging (NIA), which has 131 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Placebo capsules is the first listed.
NCT00117403 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00117403 about?
NCT00117403 is a clinical study titled "Anti-Oxidant Treatment of Alzheimer's Disease". The purpose of this study is to examine the safety and effectiveness of two anti-oxidant treatment regimens in patients with mild to moderate Alzheimer's disease. The anti-oxidant treatments include vitamin E + C + alpha-lipoic acid, and Coenzyme Q (CoQ).
What is the current status of trial NCT00117403?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 75 participants. The study started on 2006-01. Estimated completion is 2007-09.
What interventions are being tested in trial NCT00117403?
The interventions under investigation include: Placebo capsules (DRUG), Vitamin E, Vitamin C, and Alpha-lipoic Acid (DRUG), Coenzyme Q (DRUG), Placebo wafers (DRUG).
Who is sponsoring clinical trial NCT00117403?
This trial is sponsored by National Institute on Aging (NIA), which has 131 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.